Keros Swings to $87M Net Income on $244M Revenue in 2025 10-K, Boosted by Takeda Deal
KROS sits 51% above its 52-week low of $9.12.
Summary
Keros Therapeutics reported strong full-year 2025 financial results in its 10-K filing, posting $244.1 million in total revenue and a significant turnaround to $87.0 million in net income. This positive performance was primarily driven by a $205.4 million license payment from Takeda, following the transfer of late-stage development rights for elritercept. The company also improved operating income to $67.6 million from a loss in the prior year, partly due to reduced R&D spend as clinical activities shifted to partners. With $287 million in cash and equivalents, Keros projects a funding runway into the first half of 2028, providing stability as it continues to advance its partnered and retained programs. This comprehensive financial update provides critical insight into the company's operational and strategic achievements.
At the time of this announcement, KROS was trading at $13.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $419.5M. The 52-week trading range was $9.12 to $22.55. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.